▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Hims & Hers Health (NYSE: HIMS)

$52.63

(-9.1%)

-$5.24

Price as of October 3, 2025, 3:58 p.m. ET

Hims & Hers Health Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
HIMS	+205.38%	+450.50%	+40.63%	+491%
S&P	+17.62%	+100.55%	+14.92%	+123%

Hims & Hers Health Company Info

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

News & Analysis

The Fool has written over 200 articles on Hims & Hers Health.

Why Hims & Hers Stock Slipped Today

Investors generally aren't fond of C-suite changes in relatively young businesses.

Eric Volkman | Oct 3, 2025

I'm Downgrading Hims & Hers Stock

The fast-growing company is taking investors on a roller-coaster ride.

Parkev Tatevosian, CFA | Sep 24, 2025

Huge News for Hims & Hers Stock

Travis Hoium | Sep 16, 2025

Testosterone could be a huge growth market for Hims & Hers.

How to Invest in Hims & Hers Health (HIMS)

Rachel Warren | Sep 12, 2025

4 Top Stocks to Buy in September

Neil Rozenbaum | Sep 4, 2025

Here are four stocks to buy now that could offer investors upside in both the short and long term.

Where Will Hims & Hers Be in 5 Years?

Rick Orford | Aug 11, 2025

Could this be the telehealth breakout Wall Street is underestimating?

Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?

Geoffrey Seiler | Aug 10, 2025

The stock remains very volatile.

Why Hims & Hers Stock Sank This Week

Brett Schafer | Aug 9, 2025

The telehealth platform is growing quickly but is in the middle of a legal battle.

Valuation

Podcast Episodes

The Great Rule Breakers Healthcare Debate- Progyny or Hims & Hers?

A Healthcare Debate: Progyny vs. Hims & Hers

Motley Fool analysts take a look.

Motley Fool Staff | Sep 26, 2025

Breaking Up is Hard to Do- It's Not Me, It's You

This Weight Loss Partnership Was a Short One

None

Motley Fool Staff | Jun 26, 2025

Dunkin', Kendrick on Offense at Super Bowl

Digesting Super Bowl Ads, Dunkin' & Starbucks Plans, and Some Weight Loss Drug News

The big game didn't live up to the big billing, but there was plenty to take in during commercial breaks and halftime.

Motley Fool Staff | Feb 19, 2025

A New Name in Weight Loss Drugs

Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option.

Motley Fool Staff | May 28, 2024